Literature DB >> 18434977

Quality of life in myelodysplastic syndromes. A special report from the Myelodysplastic Syndromes Foundation, Inc.

Kathleen Heptinstall1.   

Abstract

Patients diagnosed with myelodysplastic syndromes (MDS) typically report that they have no idea what MDS is. The heavy physical toll of MDS and its management, such as the need for frequent blood work, blood transfusions, red cells or platelets, and physician visits, as well as the debilitating fatigue experienced by some patients, often leads to a diminished quality of life (QoL). The impact of MDS on QoL is much greater than is generally appreciated, and though difficult to quantify, data that document the wide-ranging effects of MDS on patients' lives-both negative and positive--are accumulating. A broadened understanding of QoL aspects of MDS by physicians and nurses--the impact of an MDS diagnosis, of living with MDS every day, and of MDS-specific management approaches and treatments-can only improve clinicians' communication with, and care of, these patients. This special report highlights QoL findings from patient and caregiver forums conducted by The MDS Foundation, Inc. in the United States and in Europe.

Entities:  

Mesh:

Year:  2008        PMID: 18434977

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  6 in total

1.  Costs and quality of life in patients with myelodysplastic syndromes.

Authors:  Carlo Lucioni; Carlo Finelli; Silvio Mazzi; Esther N Oliva
Journal:  Am J Blood Res       Date:  2013-08-19

Review 2.  Palliative and End-of-Life Care in Myelodysplastic Syndromes.

Authors:  Myles Nickolich; Areej El-Jawahri; Thomas W LeBlanc
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

3.  Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study.

Authors:  Jesse D Troy; Carlos M de Castro; Mary Ruth Pupa; Greg P Samsa; Amy P Abernethy; Thomas W LeBlanc
Journal:  J Natl Compr Canc Netw       Date:  2018-03       Impact factor: 11.908

Review 4.  Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens.

Authors:  Wael Saber; Mary M Horowitz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).

Authors:  Gregory A Abel; Fabio Efficace; Rena J Buckstein; Sara Tinsley; Joseph G Jurcic; Yolanda Martins; David P Steensma; Corey D Watts; Azra Raza; Stephanie J Lee; Alan F List; Robert J Klaassen
Journal:  Haematologica       Date:  2016-03-04       Impact factor: 9.941

6.  Value of transfusion independence in severe aplastic anemia from patients' perspectives - a discrete choice experiment.

Authors:  A Simon Pickard; Lynn Huynh; Jasmina I Ivanova; Todor Totev; Sophia Graham; Axel C Mühlbacher; Anuja Roy; Mei Sheng Duh
Journal:  J Patient Rep Outcomes       Date:  2018-03-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.